Mark A Merchant

List of Publications by Year
in descending order

68 papers	8,280 citations	71061 41 h-index	91828 69 g-index
70 all docs	70 docs citations	70 times ranked	12932 citing authors

#	Article	IF	Citations
1	Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature, 2012, 487, 505-509.	13.7	1,029
2	A comprehensive genetic map of the mouse genome. Nature, 1996, 380, 149-152.	13.7	853
3	A genetic map of the mouse with 4,006 simple sequence length polymorphisms. Nature Genetics, 1994, 7, 220-245.	9.4	578
4	A Novel One-Armed Anti-c-Met Antibody Inhibits Glioblastoma Growth In vivo. Clinical Cancer Research, 2006, 12, 6144-6152.	3.2	327
5	Oncogenic ERBB3 Mutations in Human Cancers. Cancer Cell, 2013, 23, 603-617.	7.7	318
6	Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E4410-7.	3.3	283
7	A Novel Tankyrase Small-Molecule Inhibitor Suppresses APC Mutationâ€“Driven Colorectal Tumor Growth. Cancer Research, 2013, 73, 3132-3144.	0.4	282
8	Quantitative locus analysis of airway hyperresponsiveness in A/J and C57BL/6J mice. Nature Genetics, 1995, 11, 150-154.	9.4	280
9	Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature, 2013, 501, 232-236.	13.7	270
10	The Cancer Stem Cell Marker Aldehyde Dehydrogenase Is Required to Maintain a Drug-Tolerant Tumor Cell Subpopulation. Cancer Research, 2014, 74, 3579-3590.	0.4	238
11	MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival. Cancer Research, 2008, 68, 4360-4368.	0.4	233
12	Enhancer Activity Requires CBP/P300 Bromodomain-Dependent Histone H3K27 Acetylation. Cell Reports, 2018, 24, 1722-1729.	2.9	231
13	Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition. Cancer Research, 2012, 72, 210-219.	0.4	228
14	Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E2987-96.	3.3	206
15	Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies. Nature Biotechnology, 2013, 31, 753-758.	9.4	167
16	Network quantification of EGFR signaling unveils potential for targeted combination therapy. Molecular Systems Biology, 2013, 9, 673.	3.2	158
17	Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development. Journal of Medicinal Chemistry, 2016, 59, 5650-5660.	2.9	123
18	A transgene insertion creating a heritable chromosome deletion mouse model of Prader-Willi and Angelman syndromes. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 9258-9263.	3.3	118

#	Article	IF	Citations
19	Suppressor of Fused Regulates Gli Activity through a Dual Binding Mechanism. Molecular and Cellular Biology, 2004, 24, 8627-8641.	1.1	117
20	The LMP2A ITAM Is Essential for Providing B Cells with Development and Survival Signals In Vivo. Journal of Virology, 2000, 74, 9115-9124.	1.5	113
21	Loss of the Serine/Threonine Kinase Fused Results in Postnatal Growth Defects and Lethality Due to Progressive Hydrocephalus. Molecular and Cellular Biology, 2005, 25, 7054-7068.	1.1	111
22	A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types. Npj Precision Oncology, 2018, 2, 7.	2.3	107
23	Therapeutic Targeting of the CBP/p300 Bromodomain Blocks the Growth of Castration-Resistant Prostate Cancer. Cancer Research, 2017, 77, 5564-5575.	0.4	105
24	Noncovalent Wild-typeâ€“Sparing Inhibitors of EGFR T790M. Cancer Discovery, 2013, 3, 168-181.	7.7	87
25	Disruption of IRE1Î± through its kinase domain attenuates multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 16420-16429.	3.3	78
26	GNE-781, A Highly Advanced Potent and Selective Bromodomain Inhibitor of Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP). Journal of Medicinal Chemistry, 2017, 60, 9162-9183.	2.9	77
27	Tankyrase Inhibition Causes Reversible Intestinal Toxicity in Mice with a Therapeutic Index < 1. Toxicologic Pathology, 2016, 44, 267-278.	0.9	76
28	Genome maps IV 1993. Wall chart. Science, 1993, 262, 67-82.	6.0	73
29	FGFR3 Stimulates Stearoyl CoA Desaturase 1 Activity to Promote Bladder Tumor Growth. Cancer Research, 2012, 72, 5843-5855.	0.4	73
30	Discovery of a Potent and Selective in Vivo Probe (GNE-272) for the Bromodomains of CBP/EP300. Journal of Medicinal Chemistry, 2016, 59, 10549-10563.	2.9	69
31	Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors. PLoS ONE, 2017, 12, e0185862.	1.1	67
32	Conditional activation of Pik3caH1047R in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations. Oncogene, 2013, 32, 318-326.	2.6	65
33	Venetoclax Increases Intratumoral Effector T Cells and Antitumor Efficacy in Combination with Immune Checkpoint Blockade. Cancer Discovery, 2021, 11, 68-79.	7.7	65
34	Blocking NRG1 and Other Ligand-Mediated Her4 Signaling Enhances the Magnitude and Duration of the Chemotherapeutic Response of Nonâ€“Small Cell Lung Cancer. Science Translational Medicine, 2013, 5, 171ra18.	5.8	63
35	Epstein-Barr Virus Latent Membrane Protein 2a (Lmp2a) Employs the Slp-65 Signaling Module. Journal of Experimental Medicine, 2001, 194, 255-264.	4.2	57
36	Immuno-PET of the Hepatocyte Growth Factor Receptor Met Using the 1-Armed Antibody Onartuzumab. Journal of Nuclear Medicine, 2012, 53, 1592-1600.	2.8	54

#	Article	IF	Citations
37	Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors. Cancer Cell, 2018, 34, 611-625.e7.	7.7	51
38	Modeling Targeted Inhibition of MEK and PI3 Kinase in Human Pancreatic Cancer. Molecular Cancer Therapeutics, 2015, 14, 40-47.	1.9	48
39	Clinical responses to ERK inhibition in BRAF V600E-mutant colorectal cancer predicted using a computational model. Npj Systems Biology and Applications, 2017, 3, 14.	1.4	45
40	<scp>PAK1</scp> mediates pancreatic cancer cell migration and resistance to <scp>MET</scp> inhibition. Journal of Pathology, 2014, 234, 502-513.	2.1	44
41	IRE1Î± Disruption in Triple-Negative Breast Cancer Cooperates with Antiangiogenic Therapy by Reversing ER Stress Adaptation and Remodeling the Tumor Microenvironment. Cancer Research, 2020, 80, 2368-2379.	0.4	44
42	The Effects of the Epstein-Barr Virus Latent Membrane Protein 2a on B Cell Function. International Reviews of Immunology, 2001, 20, 805-835.	1.5	43
43	Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study. Journal of Medicinal Chemistry, 2015, 58, 8877-8895.	2.9	43
44	Hepatocyte Growth Factor, a Determinant of Airspace Homeostasis in the Murine Lung. PLoS Genetics, 2013, 9, e1003228.	1.5	42
45	RTK-Dependent Inducible Degradation of Mutant PI3KÎ± Drives GDC-0077 (Inavolisib) Efficacy. Cancer Discovery, 2022, 12, 204-219.	7.7	40
46	LMP2A Survival and Developmental Signals Are Transmitted through Btk-Dependent and Btk-Independent Pathways. Virology, 2001, 291, 46-54.	1.1	38
47	Regulation of Tumor-Associated Myeloid Cell Activity by CBP/EP300 Bromodomain Modulation of H3K27 Acetylation. Cell Reports, 2019, 27, 269-281.e4.	2.9	37
48	Latent Membrane Protein 2A, a Viral B Cell Receptor Homologue, Induces CD5+B-1 Cell Development. Journal of Immunology, 2004, 172, 5329-5337.	0.4	34
49	Preclinical Disposition of GDC-0973 and Prospective and Retrospective Analysis of Human Dose and Efficacy Predictions. Drug Metabolism and Disposition, 2012, 40, 919-927.	1.7	34
50	Discovery of Novel Allosteric Mitogen-Activated Protein Kinase Kinase (MEK) 1,2 Inhibitors Possessing Bidentate Ser212 Interactions. Journal of Medicinal Chemistry, 2012, 55, 4594-4604.	2.9	32
51	Pharmacokinetic drivers of toxicity for basic molecules: Strategy to lower pKa results in decreased tissue exposure and toxicity for a small molecule Met inhibitor. Toxicology and Applied Pharmacology, 2013, 266, 86-94.	1.3	32
52	Onartuzumab (MetMAb): Using Nonclinical Pharmacokinetic and Concentrationâ€“Effect Data to Support Clinical Development. Clinical Cancer Research, 2013, 19, 5068-5078.	3.2	30
53	WW- and SH3-Domain Interactions with Epstein-Barr Virus LMP2A. Experimental Cell Research, 2000, 257, 332-340.	1.2	29
54	Functional screening implicates miR-371-3p and peroxiredoxin 6 in reversible tolerance to cancer drugs. Nature Communications, 2016, 7, 12351.	5.8	28

#	Article	IF	Citations
55	PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts. Cancer Chemotherapy and Pharmacology, 2013, 71, 133-143.	1.1	27
56	Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma. Molecular Cancer Therapeutics, 2017, 16, 1729-1738.	1.9	27
57	HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors. Molecular Cancer Therapeutics, 2013, 12, 1122-1130.	1.9	22
58	Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program. PLoS ONE, 2015, 10, e0139679.	1.1	22
59	CRAF dimerization with ARAF regulates KRAS-driven tumor growth. Cell Reports, 2022, 38, 110351.	2.9	18
60	Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a 5-Fluoro-4-(3H)-quinazolinone Aryl Urea pan-RAF Kinase Inhibitor. Journal of Medicinal Chemistry, 2021, 64, 3940-3955.	2.9	17
61	Transcriptional Subtypes Resolve Tumor Heterogeneity and Identify Vulnerabilities to MEK Inhibition in Lung Adenocarcinoma. Clinical Cancer Research, 2021, 27, 1162-1173.	3.2	13
62	Structure of SAP18:Â A Ubiquitin Fold in Histone Deacetylase Complex Assemblyâ€¡. Biochemistry, 2006, 45, 11974-11982.	1.2	12
63	Nonclinical Evaluation of the Serum Pharmacodynamic Biomarkers HGF and Shed MET following Dosing with the Anti-MET Monovalent Monoclonal Antibody Onartuzumab. Molecular Cancer Therapeutics, 2014, 13, 540-552.	1.9	12
64	MET Suppresses Epithelial VEGFR2 via Intracrine VEGF-induced Endoplasmic Reticulum-associated Degradation. EBioMedicine, 2015, 2, 406-420.	2.7	12
65	Preclinical absorption, distribution, metabolism, excretion, and pharmacokineticâ€“pharmacodynamic modelling ofN-(4-(3-((3S,4R)-1-ethyl-3-fluoropiperidine-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-4-yloxy)-3-fluorophenyl)-2-(4-fluorophenyl)-3-oxo-2,3-d a novel MET kinase inhibitor. Xenobiotica, 2011, 41, 327-339.	0.5	9
66	Redesigning a Monospecific Anti-FGFR3 Antibody to Add Selectivity for FGFR2 and Expand Antitumor Activity. Molecular Cancer Therapeutics, 2015, 14, 2270-2278.	1.9	6
67	Conformation-locking antibodies for the discovery and characterization of KRAS inhibitors. Nature Biotechnology, 2022, 40, 769-778.	9.4	5
68	Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a Pyridopyridazinone pan-RAF Kinase Inhibitor. ACS Medicinal Chemistry Letters, 2021, 12, 791-797.	1.3	3